Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,057,186
  • Shares Outstanding, K 68,515
  • Annual Sales, $ 297,200 K
  • Annual Income, $ -11,840 K
  • EBIT $ 15 M
  • EBITDA $ 31 M
  • 60-Month Beta 0.03
  • Price/Sales 3.39
  • Price/Cash Flow 198.30
  • Price/Book 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.05
  • Low Estimate 0.00
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.68 +21.69%
on 11/05/25
16.50 -6.48%
on 11/06/25
+0.76 (+5.18%)
since 10/07/25
3-Month
11.00 +40.27%
on 08/12/25
17.08 -9.66%
on 08/08/25
+3.28 (+27.00%)
since 08/07/25
52-Week
7.31 +111.08%
on 11/21/24
17.08 -9.66%
on 08/08/25
+7.12 (+85.68%)
since 11/07/24

Most Recent Stories

More News
Pharming Group Announces Restructuring to Cut Costs and Boost Growth

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

PHAR : 15.43 (+4.97%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 1.1900 (+0.85%)
KNSA : 38.37 (-0.67%)
CRMD : 10.76 (-0.19%)
PHAR : 15.43 (+4.97%)
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...

KNSA : 38.37 (-0.67%)
CRMD : 10.76 (-0.19%)
CPRX : 21.39 (+1.91%)
PHAR : 15.43 (+4.97%)
Pharming Group to participate in September investor conferences

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the...

PHAR : 15.43 (+4.97%)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

PHAR : 15.43 (+4.97%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

KA : 0.5746 (-30.69%)
XFOR : 3.71 (+5.85%)
PHAR : 15.43 (+4.97%)
APRE : 1.2300 (+2.50%)
Pharming Group to report second quarter and first half 2023 financial results on August 3

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter...

PHAR : 15.43 (+4.97%)
Pharming announces sale of priority review voucher

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive...

PHAR : 15.43 (+4.97%)
Pharming Group to attend the following Investor Conferences in June

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following...

PHAR : 15.43 (+4.97%)
Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

PHAR : 15.43 (+4.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company's product portfolio includes C1INH. Pharming Group N.V. is based in Leiden, The Netherlands....

See More

Key Turning Points

3rd Resistance Point 17.90
2nd Resistance Point 17.08
1st Resistance Point 16.25
Last Price 15.43
1st Support Level 14.61
2nd Support Level 13.78
3rd Support Level 12.96

See More

52-Week High 17.08
Last Price 15.43
Fibonacci 61.8% 13.35
Fibonacci 50% 12.19
Fibonacci 38.2% 11.04
52-Week Low 7.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar